	Actif À Court Terme		Date
Acadia Pharmaceuticals	USD 1.06B	14.31M	2025-12
Agios Pharmaceuticals	USD 942.05M	91.06M	2025-12
Akebia Therapeutics	USD 252.96M	5.38M	2025-12
Amgen	USD 29.06B	1.17B	2025-12
AstraZeneca	USD 28.72B	1.22B	2025-12
Bayer	EUR 32.88B	873M	2025-09
BioMarin Pharmaceutical	USD 3.95B	98.95M	2025-12
Bristol-Myers Squibb	USD 35.63B	2.41B	2025-09
Cytokinetics	USD 916.97M	60.37M	2025-12
Eisai	JPY 840.88B	50.18B	2025-12
Eli Lilly	USD 55.63B	6.44B	2025-12
Esperion Therapeutics	USD 360.46M	17.87M	2025-09
Exelixis	USD 1.44B	41.03M	2025-12
Genmab	DKK 3.91B	127M	2025-06
Glaxosmithkline	GBP 23.98B	6.31B	2025-09
Incyte	USD 5.02B	746.01M	2025-12
Ionis Pharmaceuticals	USD 2.99B	471.01M	2025-12
MacroGenics	USD 232.09M	27.15M	2025-09
Merck	USD 47.56B	10.49B	2025-09
Moderna	USD 6.54B	54M	2025-12
Nektar Therapeutics	USD 281.36M	94.79M	2025-09
Neurocrine Biosciences	USD 2.52B	364.3M	2025-12
Novartis	USD 28.2B	2.26B	2025-09
Pfizer	USD 46.92B	3.22B	2025-09
Puma Biotechnology	USD 143.58M	7M	2025-09
Sanofi	EUR 30.95B	8.99B	2025-12
Takeda	JPY 3.12T	195.82B	2025-12
Ultragenyx Pharmaceutical	USD 643.21M	76.58M	2025-09
Xencor	USD 599.82M	81.38M	2025-12

Exelixis Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.